Pioglitazone: An agent which reduces stroke, myocardial infarction and death and is also a key component of the modern paradigm for the optimum management of type 2 diabetes

British Journal of Diabetes and Vascular Disease

Volumn 11, Issue 3, 2011, Pages 113-120

  Ryder, R E J ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

cardiovascular disease; exenatide; glitazone; GLP 1 agonist; liraglutide; metformin; myocardial infarction; ominous octet; pioglitazone; rosiglitazone; stroke; type 2 diabetes; TZD

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RIMONABANT; ROSIGLITAZONE; SIBUTRAMINE; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; ARTERIAL WALL THICKNESS; BLADDER CANCER; CANCER INCIDENCE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY INTIMA MEDIA THICKNESS; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY RECANALIZATION; DEATH; DISEASE ASSOCIATION; DISEASE COURSE; ECHOGRAPHY; FEMALE; HEART FAILURE; HEART INFARCTION; HUMAN; INTRAVASCULAR ULTRASONOGRAPHY; LEG REVASCULARIZATION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; REVIEW; RISK; RISK REDUCTION; STROKE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 80052584999     PISSN: 14746514     EISSN: 17534305     Source Type: Journal    
DOI: 10.1177/1474651411412658     Document Type: Review

References (49)

1. Donnelly R., Emslie-Smith AM, Gardner ID, Morris AD ABC of arterial and venous disease: vascular complications of diabetes. BMJ 2000 ; 320: 1062-6. (Pubitemid 30198980)
2. Haffner SM, Lehto S., Ronnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998 ; 339: 229-34. (Pubitemid 28350165)
3. Adlerberth AM, Rosengren A., Wilhelmsen L. Diabetes and long-term risk of mortality from coronary and other causes in middle-aged Swedish men. A general population study. Diabetes Care 1998 ; 21: 539-45. (Pubitemid 28172931)
4. Laakso M., Lehto S. Epidemiology of macrovascular diseases in diabetes. Diabetes Rev 1997 ; 5: 294-315.
5. Reaven G. Insulin resistance, hypertension, and coronary heart disease. J Clin Hypertens 2003 ; 5: 269-74. (Pubitemid 37098487)
6. UK Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998 ; 352: 854-65.
7. Dormandy JA, Charbonnel B., Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet 2005 ; 366: 1279-89. (Pubitemid 41416583)
8. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007 ; 356: 2457-71. (Pubitemid 46919772)
9. Singh S., Loke YK, Furberg CD Thiazolidinediones and heart failure - a teleo-analysis. Diabetes Care 2007 ; 30: 2148-53.
10. BBC news, Friday 27 July 2007. Diabetes drugs 'pose heart risk'. http://news.bbc.co.uk/1/hi/health/6914434.stm Accessed August 2007.
11. Diabetes UK website, Friday 27 July 2007. Can glitazones increase heart failure risk? www.diabetes.org.uk/About-us/News-Landing-Page/Can-glitazones- increase-heartfailure-risk/ Accessed August 2007.
12. Schwartz AV, Sellmeyer, DE Thiazolidinedione therapy gets complicated: is bone loss the price of improved insulin resistance? Diabetes Care 2007 ; 30: 1670-1 (Pubitemid 46871197)
13. Home PD, Pocock SJ, Beck-Nielsen et al. Rosiglitazone evaluated for cardiac outcomes and in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009 ; 373: 2125-35.
14. Nissen SE Setting the RECORD straight. JAMA 2010 ; 303: 1194-5.
15. Medicines and Healthcare products Regulatory Agency (MHRA). Rosiglitazone (Avandia, Avandamet): Recommended withdrawal from clinical use. www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/ Safetywarningsandmessagesformedicines/CON09412121 Accessed 1 June 2011.
16. Zimmet P. Controversies in diabetes: getting to the heart of the problem. www.thelancet.com/education/at-the-limits Accessed 12 April 2011.
17. Schindler C. Influence of diabetes on the development and progression of cardiovascular disease. Br J Diab Vasc Dis 2010 ; 10: 54-6.
18. Schindler C. The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy targeting the pathogenesis? Ther Adv Cardiovasc Dis 2007 ; 1: 7-26.
19. Crouse JR Imaging atherosclerosis: state of the art. J Lipid Res 2006 ; 47: 1677-99.
20. Hodis HN, Mack WJ, LeBree L. et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998 ; 128: 262-9. (Pubitemid 28090756)
21. Mazzone T., Meyer PM, Feinstein SB et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006 ; 296: 2572-81. (Pubitemid 44903861)
22. Nicholls SJ, Sipahi I., Schoenhagen P. et al. Application of intravascular ultrasound in anti-atherosclerotic drug development. Nat Rev Drug Discov 2006 ; 5: 485-92. (Pubitemid 44136960)
23. Nissen SE, Nicholls SJ, Wolski K. et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008 ; 299: 1561-73. (Pubitemid 351482795)
24. Tzoulaki I., Molokhia M., Curcin V. et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009 Dec 3; 339: b4731. doi: 10.1136/ bmj.b4731.
25. Lincoff AM, Wolski K., Nicholls SJ, Nissen SE Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007 ; 298: 1180-8. (Pubitemid 47403104)
26. Ryder REJ Rosiglitazone versus pioglitazone in relation to cardiovascular disease in type 2 diabetes: primum non nocere. Pract Diabetes Int 2007 ; 24: 422-5.
27. Erdmann E., Dormandy JA, Charbonnel B. et al. On behalf of the PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007 ; 49: 1772-80. (Pubitemid 46629127)
28. Wilcox R., Bousser MG, Betteridge DJ et al. On behalf of the PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007 ; 38: 865-73. (Pubitemid 46568445)
29. Goldberg RB, Kendall DM, Deeg MA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005 ; 28: 1547-54. (Pubitemid 40923063)
30. Derosa G., Cicero AF, D'Angelo A. et al. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. Clin Ther 2006 ; 28: 679-688. (Pubitemid 44067262)
31. Nicholls SJ, Tuzcu EM, Sipahi I. et al. Statins, highdensity lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007 ; 297: 499-508. (Pubitemid 46220805)
32. Otvos JD, Collins D., Freedman DS et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favourably changed by gemfibrozil therapy in the veterans affairs high-density lipoprotein intervention trial. Circulation 2006 ; 113: 1556-63. (Pubitemid 43739414)
33. Manninen V. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988 ; 260: 641-51.
34. Quinn CE, Hamilton PK, Lockhart CJ, McVeigh GE Thiazolidinediones: effects on insulin resistance and the cardiovascular system. Br J Pharmacol 2008 ; 153: 636-45. (Pubitemid 351271751)
35. Lemay DG, Hwang DH Genome-wide identification of peroxisome proliferator response elements using integrated computational genomics. J Lipid Res 2006 ; 47: 1583-7. (Pubitemid 44079913)
36. El-Hage J. Peroxisome proliferato ractivated receptor (PPAR) agonists: pre-clinical and clinical cardiac safety considerations. 2006 www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ucm119071.pdf Accessed April 2011.
37. Nesto RW, Bell D., Bonow RO et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004 ; 27: 256-63. (Pubitemid 38196741)
38. Erdmann E., Charbonnel B., Wilcox RG et al. PROactive investigators. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007 ; 30: 2773-8. (Pubitemid 350083116)
39. Drummond R., Fisher M. Fractures, heart failure and fears of myocardial ischaemia: has the RECORD stuck for rosiglitazone and the thiazolidinediones? Pract Diabetes Int 2007 ; 24: 324-7. (Pubitemid 47180169)
40. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006 ; 355: 2427-43. (Pubitemid 44903747)
41. Takeda. Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS (pioglitazone HCl) tablets for type 2 diabetes mellitus (Letter to Health Care Providers), March 2007. www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm150451.htm Accessed April 2011.
42. DeFronzo RA Banting Lecture: from the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009 ; 58: 773-95.
43. DeFronzo RA Holistic approach to glycaemic control. Online webcast lecture on website of the European Association for the Study of Diabetes (EASD). http://easd.conference2web.com/play/2010/307990031 Accessed 16 April 2011.
44. Yeung NG, Husain I., Waterfall N. Diabetes mellitus and bladder cancer - an epidemiological relationship? Pathology Oncology Research 2003 ; 91: 30-31. (Pubitemid 36604536)
45. Lewis JD, Ferrara A., Peng T., et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011 Apr;34: 916-22.
46. Suzuki S., Arnold LL, Pennington KL, et al. Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. Toxicol Sci 2010 ; 113: 349-57
47. Piccinni C., Motola D., Marchesini G., Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care. 2011 Jun; 34: 1369-71. Epub 2011 Apr 22.
48. European Medicines Agency updates on ongoing benefit-risk review of pioglitazone-containing medicines. 23 June 2011. http://www.ema.europa.eu/ema/ index.jsp?curl=pages/news-and-events/news/2011/06/news-detail-001284. jsp&murl=menus/news-and-events/news-and-events.jsp&mid= WC0b01ac058004d5c1&jsenabled=true. (accessed June 24 2011)
49. Pioglitazone and bladder cancer. A letter from the Association of BritishClinical Diabetologists (ABCD) to the Medicines and HealthcareProducts Regulatory Agency (MHRA). http://www.diabetologists.org.uk/Shared-Documents/ position-papers/ABCD-pioglitazone-submission-to-MHRA.pdf (accessed June 27 2011 )